Aripiprazole-induced reversible myopia in a patient with Tourette syndrome
Cavanna, Andrea E Capriolo, Elisa Caimi, Virginia Arienti, Gabriele Riva, Anna Nacinovich, Renata Seri, Stefano
Cavanna, Andrea E
Capriolo, Elisa
Caimi, Virginia
Arienti, Gabriele
Riva, Anna
Nacinovich, Renata
Seri, Stefano
Abstract
BACKGROUND: Myopia has been reported as a rare adverse effect of aripiprazole, a third-generation antidopaminergic medication used for the treatment of different neuropsychiatric conditions, including psychotic disorders, affective disorders, and obsessive-compulsive disorder.
CASE DESCRIPTION: We document the rare case of a 29-year-old woman diagnosed with a neurodevelopmental tic disorder (Tourette syndrome) who developed bilateral myopia while taking aripiprazole 15 mg daily as a first-line anti-tic agent. Her myopia completely regressed following a decrease in the dose of aripiprazole from 15 mg to 10 mg daily.
DISCUSSION: To date, a total of 11 cases presenting with aripiprazole-induced reversible myopia (9 females, age range 19-34 years) have been reported. In addition to broadening the spectrum of the treated conditions, our case report raises the possibility of dose-dependent mechanisms underlying the development of myopia, at least in selected cases.
MIDER Authors
Affiliations
Birmingham and Solihull Mental Health NHS Foundation Trust; University of Birmingham
Date
2025-09-16
Type
Article
Collections
Citation
Cavanna AE, Capriolo E, Caimi V, Arienti G, Riva A, Nacinovich R, Seri S. Aripiprazole-induced reversible myopia in a patient with Tourette syndrome. Neurol Sci. 2025 Nov;46(11):6027-6030. doi: 10.1007/s10072-025-08496-x. Epub 2025 Sep 16.